Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Ridker PM, et al. Among authors: eby cs. N Engl J Med. 2003 Apr 10;348(15):1425-34. doi: 10.1056/NEJMoa035029. Epub 2003 Feb 24. N Engl J Med. 2003. PMID: 12601075 Free article. Clinical Trial.
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.
Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C; ATTRACT Trial Investigators. Vedantham S, et al. N Engl J Med. 2017 Dec 7;377(23):2240-2252. doi: 10.1056/NEJMoa1615066. N Engl J Med. 2017. PMID: 29211671 Free PMC article. Clinical Trial.
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH; COAG Investigators. Kimmel SE, et al. Among authors: eby cs. N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251361 Free PMC article. Clinical Trial.
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, Eriksson N, Anderson JL, Pirmohamed M, Limdi NA, Pendleton RC, McMillin GA, Burmester JK, Kurnik D, Stein CM, Caldwell MD, Eby CS, Rane A, Lindh JD, Shin JG, Kim HS, Angchaisuksiri P, Glynn RJ, Kronquist KE, Carlquist JF, Grice GR, Barrack RL, Li J, Gage BF. Horne BD, et al. Among authors: eby cs. Thromb Haemost. 2012 Feb;107(2):232-40. doi: 10.1160/TH11-06-0388. Epub 2011 Dec 21. Thromb Haemost. 2012. PMID: 22186998 Free PMC article.
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.
Kimmel SE, French B, Anderson JL, Gage BF, Johnson JA, Rosenberg YD, Geller NL, Kasner SE, Eby CS, Joo J, Caldwell MD, Goldhaber SZ, Hart RG, Cifelli D, Madigan R, Brensinger CM, Goldberg S, Califf RM, Ellenberg JH. Kimmel SE, et al. Among authors: eby cs. Am Heart J. 2013 Sep;166(3):435-41. doi: 10.1016/j.ahj.2013.04.009. Epub 2013 Jul 12. Am Heart J. 2013. PMID: 24016491 Free PMC article. Clinical Trial.
Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.
Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Hendrie P, Kuderer N, Lee A, Lee JT, Lovrincevic M, Millenson MM, Neff AT, Ortel TL, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Yee GC, Zakarija A, McMillian N, Engh AM. Streiff MB, et al. J Natl Compr Canc Netw. 2015 Sep;13(9):1079-95. doi: 10.6004/jnccn.2015.0133. J Natl Compr Canc Netw. 2015. PMID: 26358792
Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.
Lindley KJ, Limdi NA, Cavallari LH, Perera MA, Lenzini P, Johnson JA, Wu AHB, Ridker PM, King CR, Eby CS, Patel S, Shah SV, Beasley TM, Li J, Gage BF. Lindley KJ, et al. Among authors: eby cs. Clin Pharmacol Ther. 2022 Apr;111(4):950-955. doi: 10.1002/cpt.2549. Epub 2022 Feb 27. Clin Pharmacol Ther. 2022. PMID: 35108398
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Gage BF, et al. Clin Pharmacol Ther. 2008 Sep;84(3):326-31. doi: 10.1038/clpt.2008.10. Epub 2008 Feb 27. Clin Pharmacol Ther. 2008. PMID: 18305455 Free PMC article.
Venous thromboembolic disease.
Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao S, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, Yee GC, Zakarija A. Streiff MB, et al. J Natl Compr Canc Netw. 2011 Jul 1;9(7):714-77. doi: 10.6004/jnccn.2011.0062. J Natl Compr Canc Netw. 2011. PMID: 21715723 Free PMC article. No abstract available.
109 results